← Human Trials & Peer-Reviewed Studies
Serum IGF-1 to IGFBP-3 Molar Ratio: A Promising Diagnostic Tool for Growth Hormone Deficiency in Children
Plain-language guide to PMID 36251796 (2023): observational study study of IGF-1 LR3 in 235 children.
Key Facts
- PMID
- 36251796
- Journal
- The Journal of clinical endocrinology and metabolism
- Year
- 2023
- Study type
- Observational Study
- Authors
- Haj-Ahmad LM et al. (7 authors)
- DOI
- 10.1210/clinem/dgac609
What This Study Did, in Plain Language
What Was Tested
Researchers studied IGF-1 LR3 in this observational study publication.
This study aimed to investigate the performance of the IGF-1/IGFBP-3 ratio, independently and in combination with serum IGF-1 and IGFBP-3, in the diagnosis of growth hormone deficiency (GHD) in children with short stature (SS).
Why It Was Studied
The serum insulin-like growth factor-1 (IGF-1)/insulin-like growth factor binding protein-3 (IGFBP-3) ratio has various potential applications in growth hormone-related disorders.
Who Took Part
According to the abstract, 235 children were involved.
PubMed indexes the participants as children.
A 7-year cross-sectional observational study was conducted on 235 children with SS.
Participants with known disorders that may affect IGF-1 other than GHD were excluded.
How the Study Was Run
A time span of 1 year appears in the methods.
Participants were classified into GHD (n = 64) and non-GHD (n = 171) groups.
GHD was defined as a slow growth rate (<25th percentile over 1 year) and suboptimal growth hormone (GH) response to 2 GH stimulation tests (peak GH < 6.25 ng/mL using the DiaSorin Liaison assay).
The sensitivity and specificity of serum IGF-1, IGFBP-3, and IGF-1/IGFBP-3 molar ratio, independently and in various combinations, were determined.
What Was Measured
Topics PubMed links to this paper include Insulin-Like Growth Factor I, Insulin-Like Growth Factor Binding Protein 3, Cross-Sectional Studies, Growth Hormone, Human Growth Hormone, Dwarfism, Pituitary and Hypopituitarism.
Author keywords: IGF-1, IGF-1/IGFBP-3 ratio, IGFBP-3, children, growth hormone deficiency and short stature.
What This Means in Plain Language
This is a observational study of IGF-1 LR3 in 235 children over 1 year.
The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2023 (The Journal of clinical endocrinology and metabolism), a journal based in United States.
More context: the IGF-1 LR3 compound page, all human trials.
Our Notes on the Compound
IGF-1 LR3: A modified IGF-1 analog that escapes binding proteins, so it stays active ≥24 h.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.